9-(2'-O-Acetyl-3'-bromo-3'-deoxy-β-D-xylofuranosyl)adenine | 42867-78-7

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 9-(2'-O-Acetyl-3'-bromo-3'-deoxy-β-D-xylofuranosyl)adenine
• 英文别名: 9-(2-O-acetyl-3-bromo-3-deoxy-β-D-xylofuranosyl)adenine；O²-acetyl-1-(6-amino-purin-9-yl)-3-bromo-β-D-1,3-dideoxy-xylofuranose；9-(2-O-Acetyl-3-brom-3-deoxy-β-D-xylofuranosyl)-adenin；9-(2-O-Acetyl-3-bromo-3-deoxy-beta-D-xylofuranosyl)-9H-purin-6-amine；[(2R,3S,4S,5R)-2-(6-aminopurin-9-yl)-4-bromo-5-(hydroxymethyl)oxolan-3-yl] acetate
• CAS: 42867-78-7
• 化学式: C₁₂H₁₄BrN₅O₄
• 分子量: 372.178
• InChiKey: HEXFXOZQSQVMCO-MCOZSMFQSA-N

物化性质

• 熔点：
  207 °C
• 沸点：
  611.3±65.0 °C(Predicted)
• 密度：
  2.05±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  125
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  9-(2'-O-Acetyl-3'-bromo-3'-deoxy-β-D-xylofuranosyl)adenine 在 palladium on activated charcoal sodium hydroxide 、 sodium acetate 作用下， 生成 虫草素 、 2',3'-双脱氧腺苷
  参考文献：
  名称：

  Synthesis of 2′,3′-Dideoxypurinenucleosides via the Palladium Catalyzed Reduction of 9-(2,5-Di-O-acetyl-3-bromo-3-deoxy-β-d-xylofuranosyl)purine Derivatives

  摘要：

  Practical method to produce 2',3'-dideoxypurinenucleosides from 9-(2,5-di-O-acetyl-3-bromo-3-deoxy-beta-D-xylofuranosyl)purines (1) was developed. High ratio of 2',3 '-dideoxynucleoside to 3'-deoxyribonucleoside was obtained by Selecting the reaction conditions (solvent, pH and/or base), or changing 2'-acyloxy leaving group. The reaction mechanism was studied by deuteration experiments of 1a and 1-(3,5-di-O-acetyl-2-bromo-2-deoxy-beta-D-ribofuranosyl)thymine (12).

  DOI：

  10.1080/07328319608002368
• 作为产物：
  描述：

  9-(2-O-acetyl-3-bromo-3-deoxy-5-O-(2,4,4-trimethyl-5-oxo-1,3-dioxolan-2-yl)-β-D-xylofuranosyl)adenine 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 0.5h， 以87%的产率得到9-(2'-O-Acetyl-3'-bromo-3'-deoxy-β-D-xylofuranosyl)adenine
  参考文献：
  名称：

  Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation

  摘要：

  所述的发明是关于一种用于在宿主中（包括动物，特别是人类）使用一般式（I）-（XXIII）的核苷或其药用可接受的盐或前药，对Flaviviridae（包括BVDV和HCV）、Orthomyxoviridae（包括流感A和B）或Paramyxoviridae（包括RSV）感染，或与异常细胞增殖相关的疾病进行座位的组合物和方法。该发明还提供了一种有效的过程，用于使用实时聚合酶链反应（“RT-PCR”）在宿主中定量病毒载量，特别是BVDV、HCV或西尼罗河病毒载量。此外，该发明还揭示了可以与样本中存在的病毒量成比例发出荧光的探针分子。

  公开号：

  US10100076B2

文献信息

• Nucleotides. Part XXXIVSynthesis of Modified Oligomeric 2?-5?A Analogues: Potential Antiviral Agents
  作者：Piet Herdewijn、Klaus Ruf、Wolfgang Pfleiderer

  DOI：10.1002/hlca.19910740104

  日期：1991.1.30

  right positions. Their condensations with the intermediary dimeric 2′-terminal phosphodiesters 48 and 49 led to the fully protected 2′–5′-trimers 50–58 which were deblocked to form the free 2′–5′-trimers 59–63. Easy elimination of HBr on deprotection did not allow to form the trimeric (3′-bromo-3′-deoxy-β-D-xylofuranosyl)adenine analogue but only 63 carrying an unsaturated sugar moiety instead. The newly

  一系列新的2'–5'-寡核苷酸三聚体，其带有9-（2'，3'-脱水-β-D-核呋喃糖基）-（59），9-（3'-脱氧-β-D-甘油- pent-3-enofuranosyl）-（63），9-（3'-azido-3'-deoxy-β-D-xylofuranosyl）-（62）和9-（3'-halo-3'-deoxy-β通过磷酸三酯法合成了在2'-末端的-D-二呋喃呋喃糖基）腺嘌呤（60和61）部分。的适当的保护，改性单体结构单元（6，9，16，19，27，33，36，37，和43通常通过一系列反应将保护基团引入正确的位置来获得）。他们与中间商二聚体2'-终端磷酸二酯缩合48和49导致了充分的保障2'，5'-三聚体50-58，其被解封，形成游离'，5'-三聚体59 - 63。脱保护时容易消除HBr不允许形成三聚（3'-溴-3'-脱氧-β-D-木呋喃糖基）腺嘌呤类似物，而仅形成63个带有不饱和糖
• Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation
  申请人：Stuyver Lieven

  公开号：US20110269707A1

  公开（公告）日：2011-11-03

  The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.

  本公开发明涉及一种用于治疗Flaviviridae（包括BVDV和HCV）、Orthomyxoviridae（包括甲型和乙型流感）或Paramyxoviridae（包括RSV）感染或与异常细胞增殖相关的条件的组合物和方法，适用于宿主，包括动物，特别是人类，使用通式（I）-（XXIII）的核苷或其药学上可接受的盐或前药。本发明还提供了一种有效的过程，用于定量病毒载量，特别是BVDV、HCV或西尼罗河病毒载量，在宿主中使用实时聚合酶链反应（“RT-PCR”）。此外，本发明还揭示了探针分子，可以与样品中存在的病毒数量成比例地发出荧光。
• MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION
  申请人：GILEAD SCIENCES, INC.

  公开号：US20140057863A1

  公开（公告）日：2014-02-27

  The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.

  本公开发明涉及一种用于治疗Flaviviridae（包括BVDV和HCV）、Orthomyxoviridae（包括甲型和乙型流感病毒）或Paramyxoviridae（包括RSV）感染或与异常细胞增殖相关的条件的组合物和方法，适用于宿主，包括动物，特别是人类，使用一种核苷酸的一般式（I）-（XXIII）或其药学上可接受的盐或前药。本发明还提供了一种有效的过程，用于定量病毒载量，特别是BVDV、HCV或West Nile病毒载量，在宿主中使用实时聚合酶链反应（“RT-PCR”）。此外，本发明还揭示了可以与样品中存在的病毒数量成比例发光的探针分子。
• Nucleic Acid-Related Compounds. 88. Efficient Conversions of Ribonucleosides into Their 2',3'-Anhydro, 2'(and 3')-Deoxy, 2',3'-Didehydro-2',3'-dideoxy, and 2',3'-Dideoxynucleoside Analogs
  作者：Morris J. Robins、John S. Wilson、Danuta Madej、Nicholas H. Low、Fritz Hansske、Stanislaw F. Wnuk

  DOI：10.1021/jo00129a034

  日期：1995.12

  Treatment of purine, pyrimidine, and modified purine (antibiotic) ribonucleosides with 2-acetoxy-2-methylpropanoyl (alpha-acetoxyisobutyryl) bromide in acetonitrile gave mixtures of 2',3'-bromohydrin acetates with different O5' substituents. Significant amounts of 5'-unprotected (hydroxyl) bromo acetates were obtained in some cases, and formation of 2',3'-O-isopropylidene derivatives as minor byproducts was detected for the first time. Acid-catalyzed nucleophilic displacement of chloride by bromide occurred with 2-amino-6-chloropurine riboside, but no substitution of fluoride by bromide was detected with 6-amino-2-fluoropurine riboside. Treatment of the trans bromo acetate mixtures obtained from purine-type nucleosides with Dowex 1 x 2 (OH-) in methanol gave the 2',3'-anhydro (ribo epoxide) compounds. Radical-mediated hydrogenolytic debromination and deprotection gave 2'- and 3'-deoxynucleosides. Treatment of the bromo acetate mixtures with zinc-copper couple or acetic acid-activated zinc effected reductive elimination, and deprotection gave 2',3'-didehydro-2',3'-dideoxy compounds which were hydrogenated to give 2',3'-dideoxynucleosides. A number of these analogues have potent inhibitory activity against AIDS and hepatitis B viruses. New C-13 NMR data for several types of unsaturated-sugar nucleosides are tabulated. These procedures are directly applicable for the preparation of L-didehydro-dideoxy and L-dideoxy nucleoside analogues.
• A mild conversion of vicinal diols to alkenes. Efficient transformation of ribonucleosides into 2′-ene and 2t',3′-dideoxynucleosides
  作者：Morris J. Robins、Fritz Hansske、Nicholas H. Low、Ja In Park

  DOI：10.1016/s0040-4039(00)99885-x

  日期：1984.1